Y. Omuro

Clinical characteristics of patients with metastatic breast cancer with complete remission following systemic treatment (1998)

Yamamoto, N, Katsumata, N, Watanabe, T, Omuro, Y, Ando, M, Narabayashi, M, ...

A phase I trial of docetaxel and 5-day continuous infusion of 5-fluorouracil in patients with advanced or recurrent breast cancer.

Ando, M., Watanabe, T., Sasaki, Y., Ying, D. F., Omuro, Y., Katsumata, N., ...

To determine the maximum-tolerated doses (MTDs), the dose-limiting toxicities (DLTs) and the recommended doses for further trials of docetaxel in combination with a 5-day continuous infusion of...

Dose escalation and pharmacokinetic study of a humanized anti-HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer

Tokuda, Y, Watanabe, T, Omuro, Y, Ando, M, Katsumata, N, Okumura, A, ...

We conducted a phase I pharmacokinetic dose escalation study of a recombinant humanized anti-p185HER2 monoclonal antibody (MKC-454) in 18 patients with metastatic breast cancer refractory to...